Literature DB >> 12091265

Economic impact of personality disorders in UK primary care attenders.

Alison Rendu1, Paul Moran, Anita Patel, Martin Knapp, Anthony Mann.   

Abstract

BACKGROUND: The economic impact of personality disorders on UK health services is unknown. AIMS: To test the hypothesis that people with personality disorders have higher mean health and non-health costs compared with those without personality disorders.
METHOD: Prospective cohort study design. A total of 303 general practice attenders were followed-up I year after they had been assessed for the presence of personality disorders. Costs were estimated in pound sterling at 1999 price levels.
RESULTS: The mean total cost for patients with personality disorders was pound sterling 3094 (s.d.=5324) compared with pound sterling 1633 (s.d.=3779) for those without personality disorders. Personality disorders were not independently associated with increased costs. Multivariate analyses identified the presence of a significant interaction between personality disorders and common mental disorders and increased total costs (coefficient=499, 95% CI 180.1-626.2, P=0.002).
CONCLUSIONS: Personality disorders are not independently associated with increased costs. An interaction between personality disorders and common mental disorders significantly predicts increased total costs.

Entities:  

Mesh:

Year:  2002        PMID: 12091265     DOI: 10.1192/bjp.181.1.62

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  8 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Effects of personality disorders on functioning and well-being in major depressive disorder.

Authors:  Andrew E Skodol; Carlos M Grilo; Maria E Pagano; Donna S Bender; John G Gunderson; M Tracie Shea; Shirley Yen; Mary C Zanarini; Thomas H McGlashan
Journal:  J Psychiatr Pract       Date:  2005-11       Impact factor: 1.325

3.  Adaptation and Psychometric Evaluation of the Italian Version of the Attitude to Personality Disorder Questionnaire (APDQ).

Authors:  Francesca Martino; Andrea Norcini Pala; Barbara Valenti; Rossella Capelli; Domenico Berardi; Rohini Bagrodia; Marco Menchetti
Journal:  J Pers Disord       Date:  2016-10-17

4.  Screening for personality disorder: a comparison of personality disorder assessment by patient and informants.

Authors:  Paul Walters; Paul Moran; Partha Choudhury; Tennyson Lee; Anthony Mann
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

5.  Psycho-education with problem solving (PEPS) therapy for adults with personality disorder: a pragmatic multi-site community-based randomised clinical trial.

Authors:  Mary McMurran; Mike J Crawford; Joseph G Reilly; Paul McCrone; Paul Moran; Hywel Williams; Clive E Adams; Conor Duggan; Juan Delport; Diane Whitham; Florence Day
Journal:  Trials       Date:  2011-08-24       Impact factor: 2.279

6.  The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial.

Authors:  Stephen Palmer; Kate Davidson; Peter Tyrer; Andrew Gumley; Philip Tata; John Norrie; Heather Murray; Helen Seivewright
Journal:  J Pers Disord       Date:  2006-10

7.  Cost implications of treatment non-completion in a forensic personality disorder service.

Authors:  Christopher James Sampson; Marilyn James; Nick Huband; Steve Geelan; Mary McMurran
Journal:  Crim Behav Ment Health       Date:  2013-07-23

8.  Standard set of patient-reported outcomes for personality disorder.

Authors:  Valentina Prevolnik Rupel; Beth Jagger; Luz Sousa Fialho; Lisa-Marie Chadderton; Timea Gintner; Anroud Arntz; Åse-Line Baltzersen; Julia Blazdell; Jan van Busschbach; Marika Cencelli; Andrew Chanen; Charlotte Delvaux; Fieke van Gorp; Lucie Langford; Brian McKenna; Paul Moran; Karla Pacheco; Carla Sharp; Wei Wang; Karen Wright; Mike J Crawford
Journal:  Qual Life Res       Date:  2021-06-02       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.